FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications
Go back to FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications| Pfizer Inc. (NYSE: PFE) | Delayed: 30.42 +0.47 (1.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.95 | 52 Week High | $37.39 | |||
| Open | $30.51 | 52 Week Low | $28.25 | |||
| Day High | $30.65 | P/E | 18.44 | |||
| Day Low | $30.14 | EPS | $1.65 | |||
| Volume | 9,915,350 | |||||



